303 related articles for article (PubMed ID: 31276163)
1. Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial.
Carneiro BA; Konda B; Costa RB; Costa RLB; Sagar V; Gursel DB; Kirschner LS; Chae YK; Abdulkadir SA; Rademaker A; Mahalingam D; Shah MH; Giles FJ
J Clin Endocrinol Metab; 2019 Dec; 104(12):6193-6200. PubMed ID: 31276163
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.
Habra MA; Stephen B; Campbell M; Hess K; Tapia C; Xu M; Rodon Ahnert J; Jimenez C; Lee JE; Perrier ND; Boraddus RR; Pant S; Subbiah V; Hong DS; Zarifa A; Fu S; Karp DD; Meric-Bernstam F; Naing A
J Immunother Cancer; 2019 Sep; 7(1):253. PubMed ID: 31533818
[TBL] [Abstract][Full Text] [Related]
3. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.
Lerario AM; Worden FP; Ramm CA; Hesseltine EA; Stadler WM; Else T; Shah MH; Agamah E; Rao K; Hammer GD
Horm Cancer; 2014 Aug; 5(4):232-9. PubMed ID: 24849545
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
Sharma P; Retz M; Siefker-Radtke A; Baron A; Necchi A; Bedke J; Plimack ER; Vaena D; Grimm MO; Bracarda S; Arranz JÁ; Pal S; Ohyama C; Saci A; Qu X; Lambert A; Krishnan S; Azrilevich A; Galsky MD
Lancet Oncol; 2017 Mar; 18(3):312-322. PubMed ID: 28131785
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
D'Angelo SP; Mahoney MR; Van Tine BA; Atkins J; Milhem MM; Jahagirdar BN; Antonescu CR; Horvath E; Tap WD; Schwartz GK; Streicher H
Lancet Oncol; 2018 Mar; 19(3):416-426. PubMed ID: 29370992
[TBL] [Abstract][Full Text] [Related]
6. Combination of Mitotane and Locoregional Treatments in Low-volume Metastatic Adrenocortical Carcinoma.
Boilève A; Mathy E; Roux C; Faron M; Hadoux J; Tselikas L; Al Ghuzlan A; Hescot S; Leboulleux S; de Baere T; Lamartina L; Deschamps F; Baudin E
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4698-e4707. PubMed ID: 34143888
[TBL] [Abstract][Full Text] [Related]
7. Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study.
Katsuya Y; Horinouchi H; Seto T; Umemura S; Hosomi Y; Satouchi M; Nishio M; Kozuki T; Hida T; Sukigara T; Nakamura K; Kuchiba A; Ohe Y
Eur J Cancer; 2019 May; 113():78-86. PubMed ID: 30991261
[TBL] [Abstract][Full Text] [Related]
8. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).
Santin AD; Deng W; Frumovitz M; Buza N; Bellone S; Huh W; Khleif S; Lankes HA; Ratner ES; O'Cearbhaill RE; Jazaeri AA; Birrer M
Gynecol Oncol; 2020 Apr; 157(1):161-166. PubMed ID: 31924334
[TBL] [Abstract][Full Text] [Related]
9. A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors.
Ma Y; Fang W; Zhang Y; Yang Y; Hong S; Zhao Y; Tendolkar A; Chen L; Xu D; Sheng J; Zhao H; Zhang L
Oncologist; 2019 Jul; 24(7):891-e431. PubMed ID: 31048330
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series.
Kambhampati S; Bauer KE; Bracci PM; Keenan BP; Behr SC; Gordan JD; Kelley RK
Cancer; 2019 Sep; 125(18):3234-3241. PubMed ID: 31154669
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial.
Kroiss M; Quinkler M; Johanssen S; van Erp NP; Lankheet N; Pöllinger A; Laubner K; Strasburger CJ; Hahner S; Müller HH; Allolio B; Fassnacht M
J Clin Endocrinol Metab; 2012 Oct; 97(10):3495-503. PubMed ID: 22837187
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.
Sharma P; Callahan MK; Bono P; Kim J; Spiliopoulou P; Calvo E; Pillai RN; Ott PA; de Braud F; Morse M; Le DT; Jaeger D; Chan E; Harbison C; Lin CS; Tschaika M; Azrilevich A; Rosenberg JE
Lancet Oncol; 2016 Nov; 17(11):1590-1598. PubMed ID: 27733243
[TBL] [Abstract][Full Text] [Related]
14. Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.
Reidy-Lagunes DL; Lung B; Untch BR; Raj N; Hrabovsky A; Kelly C; Gerst S; Katz S; Kampel L; Chou J; Gopalan A; Saltz LB
Oncologist; 2017 Sep; 22(9):1102-1106. PubMed ID: 28559412
[TBL] [Abstract][Full Text] [Related]
15. Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial.
Campbell MT; Balderrama-Brondani V; Jimenez C; Tamsen G; Marcal LP; Varghese J; Shah AY; Long JP; Zhang M; Ochieng J; Haymaker C; Habra MA
Lancet Oncol; 2024 May; 25(5):649-657. PubMed ID: 38608694
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer - a retrospective multicentre study.
Okamoto I; Sato H; Kondo T; Koyama N; Fushimi C; Okada T; Miura K; Matsuki T; Yamashita T; Omura G; Tsukahara K
Acta Otolaryngol; 2019 Oct; 139(10):918-925. PubMed ID: 31460818
[No Abstract] [Full Text] [Related]
17. Outcome of immunotherapy in adrenocortical carcinoma: a retrospective cohort study.
Remde H; Schmidt-Pennington L; Reuter M; Landwehr LS; Jensen M; Lahner H; Kimpel O; Altieri B; Laubner K; Schreiner J; Bojunga J; Kircher S; Kunze CA; Pohrt A; Teleanu MV; Hübschmann D; Stenzinger A; Glimm H; Fröhling S; Fassnacht M; Mai K; Kroiss M
Eur J Endocrinol; 2023 Jun; 188(6):485-493. PubMed ID: 37260092
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
Haddad R; Concha-Benavente F; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Kasper S; Vokes EE; Worden F; Saba NF; Tahara M; Jayaprakash V; Lynch M; Li L; Gillison ML; Harrington KJ; Ferris RL
Cancer; 2019 Sep; 125(18):3208-3218. PubMed ID: 31246283
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.
Calabrese A; Basile V; Puglisi S; Perotti P; Pia A; Saba L; Berchialla P; Porpiglia F; Veltri A; Volante M; Reimondo G; Berruti A; Terzolo M
Eur J Endocrinol; 2019 Jun; 180(6):387-396. PubMed ID: 30991359
[TBL] [Abstract][Full Text] [Related]
20. A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma.
Smith DC; Kroiss M; Kebebew E; Habra MA; Chugh R; Schneider BJ; Fassnacht M; Jafarinasabian P; Ijzerman MM; Lin VH; Mohideen P; Naing A
Invest New Drugs; 2020 Oct; 38(5):1421-1429. PubMed ID: 31984451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
